Compare SLB & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLB | ZTS |
|---|---|---|
| Founded | 1926 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.9B | 48.7B |
| IPO Year | 1996 | 2012 |
| Metric | SLB | ZTS |
|---|---|---|
| Price | $46.10 | $121.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 20 | 11 |
| Target Price | $52.11 | ★ $156.20 |
| AVG Volume (30 Days) | ★ 14.1M | 3.2M |
| Earning Date | 04-24-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.57% | 1.75% |
| EPS Growth | N/A | ★ 10.05 |
| EPS | 2.35 | ★ 6.02 |
| Revenue | ★ $30,440,000,000.00 | $9,467,000,000.00 |
| Revenue This Year | $5.44 | $5.69 |
| Revenue Next Year | $4.58 | $4.81 |
| P/E Ratio | ★ $19.56 | $20.19 |
| Revenue Growth | ★ 9.46 | 2.28 |
| 52 Week Low | $31.11 | $114.47 |
| 52 Week High | $52.45 | $172.23 |
| Indicator | SLB | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 42.32 | 46.41 |
| Support Level | $32.81 | $117.42 |
| Resistance Level | $52.17 | $130.52 |
| Average True Range (ATR) | 1.67 | 3.20 |
| MACD | -0.62 | -0.75 |
| Stochastic Oscillator | 29.86 | 40.38 |
SLB is the world's premier oilfield-services company as measured by market share. While the industry is largely fragmented, SLB holds the first or second competitive position in many of the differentiated oligopolies in which it operates. Also known as Schlumberger, the company was founded in 1926 by two brothers bearing the same last name. Today, it's most known as a global industry leader in innovation, while it focuses its strategy on its three growth engines: core, digital, and new energy businesses. Over three-fourths of its revenue base is tied to international markets, while the company boasts nearly $3 billion in digital-related revenue.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its USA business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.